Anileridine
Leritine (anileridine) is a small molecule pharmaceutical. Anileridine was first approved as Leritine on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
30 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | 1 | — | 1 |
| Wounds and injuries | D014947 | T14.8 | — | — | — | 1 | — | 1 | |
| Post-dural puncture headache | D051299 | — | — | — | 1 | — | 1 | ||
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | — | 1 |
| Colonoscopy | D003113 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | — | 1 | — | — | 1 |
| Pachyonychia congenita | D053549 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overweight | D050177 | E66.3 | — | 1 | — | — | 1 | 2 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Healthy volunteers/patients | — | 1 | 1 | — | — | — | 2 | ||
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | 1 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Arsenic poisoning | D020261 | T57.0 | 1 | 1 | — | — | — | 1 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
| Esophageal neoplasms | D004938 | C15 | — | 1 | — | — | — | 1 | |
| Adenocarcinoma | D000230 | — | 1 | — | — | — | 1 | ||
| Essential hypertension | D000075222 | I10 | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 1 | 1 | |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ANILERIDINE |
| INN | anileridine |
| Description | Anileridine is a piperidinecarboxylate ester that is the ethyl ester of isonipecotic acid in which the hydrogen alpha- to the carboxyl group is substituted by a phenyl group, and the hydrogen attached to the nitrogen is substituted by a 2-(4-aminophenyl)ethyl group. It has a role as an opioid analgesic and an opioid receptor agonist. It is a piperidinecarboxylate ester, a substituted aniline and an ethyl ester. It is functionally related to a N-[2-(4-aminophenyl)ethyl]-4-phenylisonipecotic acid. It is a conjugate base of an anileridine(2+). |
| Classification | Small molecule |
| Drug class | analgesics (meperidine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 144-14-9 |
| RxCUI | 17933 |
| ChEMBL ID | CHEMBL1201347 |
| ChEBI ID | 61203 |
| PubChem CID | 8944 |
| DrugBank | DB00913 |
| UNII ID | 71Q1A3O279 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 105 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more